Antibody, Radiology and Vaccination - Clinical Research Informer

Antibody

Radiology

Vaccination

Vir awarded $1 billion multi-year BARDA influenza contract

pharmaphorum

OCTOBER 5, 2022

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir Biotechnology’s investigational prophylactic monoclonal antibody (mAb) for seasonal and pandemic influenza viruses.

Antibody

Antibody In-Vitro Radiology Development

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

MARCH 25, 2022

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.

Antibody

Antibody In-Vivo Medicine Vaccine

Join 21,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Trending Sources

AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442

The Pharma Data

MARCH 16, 2021

AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19. Financial considerations.

Antibody

Antibody Trials Radiology Development

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

MARCH 29, 2022

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.

Antibody

Antibody In-Vivo Vaccination Vaccine

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old).

Immune Response

Immune Response Vaccination Vaccine Trials

AZD1222 US Phase III primary analysis confirms safety and efficacy

The Pharma Data

MARCH 24, 2021

76% vaccine efficacy against symptomatic COVID-19. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. 100% efficacy against severe or critical disease and hospitalisation.

Vaccine

Vaccine Vaccination Radiology Trials

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

The Pharma Data

MARCH 22, 2021

79% vaccine efficacy at preventing symptomatic COVID-19. The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo.

Trials

Trials Vaccination Vaccine Radiology

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

The Pharma Data

AUGUST 22, 2021

AZD7442 is the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial. More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.

Trials

Trials Antibody Vaccination Vaccine

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

Delveinsight

DECEMBER 10, 2020

AstraZeneca’s COVID-19 vaccine data suggest single-dose efficacy. The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate.

Gene Therapy

Gene Therapy Gene Vaccination Vaccine

New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention

The Pharma Data

NOVEMBER 18, 2021

New data from the AZD7442 COVID-19 PROVENT forestallment and Paraphernalia inpatient treatment Phase III trials both showed robust efficacity from a one- time intramuscular (IM) cure of the long- amusement antibody (LAAB) combination. About 2 of the global population is considered at increased threat of an shy response to a COVID-19 vaccine.1

Trials

Trials Antibody In-Vitro Vaccination

3 Newest COVID-19 Tests Authorized by the FDA

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. T cells generally confer longer lasting immunity than antibodies, which more readily wane over time.

Protein

Protein RNA Antibody Production

Virus that causes COVID-19 can find alternate route to infect cells

The Pharma Data

JUNE 26, 2021

All current COVID-19 vaccines and antibody-based therapeutics were designed to disrupt this route into cells, which requires a receptor called ACE2. The ability to use an alternative entry pathway opens up the possibility of evading COVID-19 antibodies or vaccines, but the researchers did not find evidence of such evasion.

Antibody

Antibody Vaccine Vaccination Research

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA

DNA Vaccination Vaccine Immune Response

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The PROVENT trial will give us more clarity in this patient population. W911QY-21-9-0001.

Trials

Trials Antibody In-Vitro Medicine

MS PORTFOLIO DEMONSTRATE POSITIVE IMPACT OF TREATMENT ON PEOPLE LIVING WITH RELAPSING MULTIPLE SCLEROSIS

The Pharma Data

APRIL 17, 2021

Biogen currently has more than 25 MS clinical trials underway including research on considerations around COVID-19 vaccination for people with MS. No Difference in Radiologic Outcomes for Natalizumab Patients on Extended Interval Dosing Compared with Standard Interval Dosing in MS PATHS – P15.210.

Clinical Trials

Clinical Trials Clinical Trials Trials Radiology

AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US

The Pharma Data

OCTOBER 6, 2021

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Juncture Use Authorization (EUA) for AZD7442, its long- production antibody (LAAB) combination, for prophylaxis of proper COVID-19. Notwithstanding, AZD7442 would be the first LAAB to take an EUA for COVID-19 precluding, If granted. AZD7442 was well- let.

Antibody

Antibody In-Vitro Trials Development

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccine

Vaccine Vaccination Antibody Life Science

Vir awarded $1 billion multi-year BARDA influenza contract

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

Webinars

Trending Sources

AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442

Webinars

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

AZD1222 US Phase III primary analysis confirms safety and efficacy

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention

3 Newest COVID-19 Tests Authorized by the FDA

Virus that causes COVID-19 can find alternate route to infect cells

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

MS PORTFOLIO DEMONSTRATE POSITIVE IMPACT OF TREATMENT ON PEOPLE LIVING WITH RELAPSING MULTIPLE SCLEROSIS

AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US

COVID-19 Pandemic Coverage

Stay Connected